Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00138762
Other study ID # A5091018
Secondary ID
Status Completed
Phase Phase 3
First received August 26, 2005
Last updated February 15, 2012
Start date July 2004
Est. completion date August 2006

Study information

Verified date February 2012
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.


Description:

For additional information please call: 1-800-718-1021


Recruitment information / eligibility

Status Completed
Enrollment 3800
Est. completion date August 2006
Est. primary completion date August 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- subjects with elevated cholesterol

Exclusion Criteria:

- Women who are pregnant or lactating, or planning to become pregnant.

- Intolerance to statin therapy resulting in withdrawal

- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors

- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
torcetrapib/atorvastatin

atorvastatin

placebo


Locations

Country Name City State
Belgium Pfizer Investigational Site Bruxelles
Belgium Pfizer Investigational Site Dottignies
Belgium Pfizer Investigational Site Ham
Belgium Pfizer Investigational Site Hasselt
Belgium Pfizer Investigational Site Hoeilaart
Belgium Pfizer Investigational Site La Louviere
Belgium Pfizer Investigational Site Leuven
Belgium Pfizer Investigational Site Wilsele
Germany Pfizer Investigational Site Beckum
Germany Pfizer Investigational Site Berlin
Germany Pfizer Investigational Site Bochum
Germany Pfizer Investigational Site Erlangen
Germany Pfizer Investigational Site Essen
Germany Pfizer Investigational Site Feldafing
Germany Pfizer Investigational Site Hamburg
Germany Pfizer Investigational Site Heidelberg
Germany Pfizer Investigational Site Homburg/Saar
Germany Pfizer Investigational Site Karlsruhe
Germany Pfizer Investigational Site Kuenzing
Germany Pfizer Investigational Site Nuernberg
Germany Pfizer Investigational Site Offenbach
Germany Pfizer Investigational Site Rodgau
Germany Pfizer Investigational Site Schwerin
Korea, Republic of Pfizer Investigational Site Seoul
Korea, Republic of Pfizer Investigational Site Suwon
Mexico Pfizer Investigational Site Mexico D.f.
Mexico Pfizer Investigational Site Mexico DF
Mexico Pfizer Investigational Site Monterrey Nuevo Leon
Mexico Pfizer Investigational Site Puebla
Mexico Pfizer Investigational Site Tlalpan D.f.
Norway Pfizer Investigational Site Bekkestua
Norway Pfizer Investigational Site Elverum
Norway Pfizer Investigational Site Honefoss
Norway Pfizer Investigational Site Jessheim
Norway Pfizer Investigational Site Kongsberg
Norway Pfizer Investigational Site Lena
Norway Pfizer Investigational Site Lierskogen
Norway Pfizer Investigational Site Molde
Norway Pfizer Investigational Site Moss
Norway Pfizer Investigational Site Oslo
Norway Pfizer Investigational Site Roverud
Norway Pfizer Investigational Site Skedsmokorset
Norway Pfizer Investigational Site Tromso
Sweden Pfizer Investigational Site Goteborg
Sweden Pfizer Investigational Site Jarfalla
Sweden Pfizer Investigational Site Linkoping
Sweden Pfizer Investigational Site Orebro
Sweden Pfizer Investigational Site Strangnas
Sweden Pfizer Investigational Site Umea
United Kingdom Pfizer Investigational Site Addlestone Surrey
United Kingdom Pfizer Investigational Site Blackpool Lancashire
United Kingdom Pfizer Investigational Site Blackpool Lancs. Fy3 7dq
United Kingdom Pfizer Investigational Site East Horsley, Leatherhead Surrey
United Kingdom Pfizer Investigational Site Garston Hertfordshire
United Kingdom Pfizer Investigational Site Middlesex Harrow
United Kingdom Pfizer Investigational Site Penzance Cornwall
United Kingdom Pfizer Investigational Site Warminster Wiltshire
United Kingdom Pfizer Investigational Site Woolwell, Plymouth Devon
United States Pfizer Investigational Site Anaheim California
United States Pfizer Investigational Site Austin Texas
United States Pfizer Investigational Site Baltimore Maryland
United States Pfizer Investigational Site Beaumont Texas
United States Pfizer Investigational Site Beaverton Oregon
United States Pfizer Investigational Site Bethesda Maryland
United States Pfizer Investigational Site Billings Montana
United States Pfizer Investigational Site Boulder Colorado
United States Pfizer Investigational Site Bryan Texas
United States Pfizer Investigational Site Carmichael California
United States Pfizer Investigational Site Charlotte North Carolina
United States Pfizer Investigational Site Chicago Illinois
United States Pfizer Investigational Site Cincinnati Ohio
United States Pfizer Investigational Site Concord North Carolina
United States Pfizer Investigational Site Concord California
United States Pfizer Investigational Site Coral Gables Florida
United States Pfizer Investigational Site Covington Louisiana
United States Pfizer Investigational Site Creve Coevr Illinois
United States Pfizer Investigational Site Dallas Texas
United States Pfizer Investigational Site Elkton Maryland
United States Pfizer Investigational Site Elyria Ohio
United States Pfizer Investigational Site Endwell New York
United States Pfizer Investigational Site Erlanger Kentucky
United States Pfizer Investigational Site Fayetteville North Carolina
United States Pfizer Investigational Site Ft. Pierce Florida
United States Pfizer Investigational Site Greenbrae California
United States Pfizer Investigational Site Greer South Carolina
United States Pfizer Investigational Site Hillsboro Oregon
United States Pfizer Investigational Site Houston Texas
United States Pfizer Investigational Site Iowa City Iowa
United States Pfizer Investigational Site Jackson Mississippi
United States Pfizer Investigational Site Jacksonville Florida
United States Pfizer Investigational Site Jefferson City Missouri
United States Pfizer Investigational Site Jupiter Florida
United States Pfizer Investigational Site Kansas City Kansas
United States Pfizer Investigational Site Kansas City Missouri
United States Pfizer Investigational Site Kingsport Tennessee
United States Pfizer Investigational Site Lake Success New York
United States Pfizer Investigational Site Lake Worth Florida
United States Pfizer Investigational Site Las Vegas Nevada
United States Pfizer Investigational Site Lincoln Nebraska
United States Pfizer Investigational Site Little Rock Arkansas
United States Pfizer Investigational Site Los Angeles California
United States Pfizer Investigational Site Louisville Kentucky
United States Pfizer Investigational Site Melbourne Florida
United States Pfizer Investigational Site Mesa Arizona
United States Pfizer Investigational Site Milwaukee Wisconsin
United States Pfizer Investigational Site Mission Viejo California
United States Pfizer Investigational Site Mobile Alabama
United States Pfizer Investigational Site Monroe North Carolina
United States Pfizer Investigational Site Nashville Tennessee
United States Pfizer Investigational Site Newark Delaware
United States Pfizer Investigational Site Newport News Virginia
United States Pfizer Investigational Site Norfolk Virginia
United States Pfizer Investigational Site Olmsted Township Ohio
United States Pfizer Investigational Site Omaha Nebraska
United States Pfizer Investigational Site Oregon Wisconsin
United States Pfizer Investigational Site Oro Valley Arizona
United States Pfizer Investigational Site Overland Park Kansas
United States Pfizer Investigational Site Palm Bay Florida
United States Pfizer Investigational Site Peoria Illinois
United States Pfizer Investigational Site Phoenix Arizona
United States Pfizer Investigational Site Portland Oregon
United States Pfizer Investigational Site Raleigh North Carolina
United States Pfizer Investigational Site Renton Washington
United States Pfizer Investigational Site Richmond Virginia
United States Pfizer Investigational Site Rochester New York
United States Pfizer Investigational Site Rockford Illinois
United States Pfizer Investigational Site Sacramento California
United States Pfizer Investigational Site Salt Lake City Utah
United States Pfizer Investigational Site San Antonio Texas
United States Pfizer Investigational Site Santa Ana California
United States Pfizer Investigational Site Scarborough Maine
United States Pfizer Investigational Site Sebastian Florida
United States Pfizer Investigational Site Slidell Louisiana
United States Pfizer Investigational Site Spartanburg South Carolina
United States Pfizer Investigational Site Stockton California
United States Pfizer Investigational Site Stuart Florida
United States Pfizer Investigational Site Sun City Arizona
United States Pfizer Investigational Site The Colony Texas
United States Pfizer Investigational Site Thouasand Oaks California
United States Pfizer Investigational Site Tulsa Oklahoma
United States Pfizer Investigational Site Tustin California
United States Pfizer Investigational Site Upland California
United States Pfizer Investigational Site Vero Beach Florida
United States Pfizer Investigational Site Walnut Creek California
United States Pfizer Investigational Site Warwick Rhode Island
United States Pfizer Investigational Site Waterbury Connecticut
United States Pfizer Investigational Site Wellington Florida
United States Pfizer Investigational Site West Palm Beach Florida
United States Pfizer Investigational Site Westlake Ohio
United States Pfizer Investigational Site Westlake Village California
United States Pfizer Investigational Site Wichita Kansas
United States Pfizer Investigational Site Williamsville New York
United States Pfizer Investigational Site Winston-Salem North Carolina
United States Pfizer Investigational Site Yakima Washington

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Belgium,  Germany,  Korea, Republic of,  Mexico,  Norway,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary LDL and HDL levels
Secondary other lipid parameters
See also
  Status Clinical Trial Phase
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed NCT02927184 - Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease Phase 2
Completed NCT04640012 - Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects Phase 1
Completed NCT03213288 - Bilberry Fruit and Black Rice Derived Anthocyanins on Lipid Status N/A
Completed NCT00382564 - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease N/A
Recruiting NCT02979704 - A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia Phase 2/Phase 3
Completed NCT02569814 - A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin Phase 1
Completed NCT02280590 - Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia Phase 4
Completed NCT02428998 - Safety for 24 Weeks Intake of Korean Red Ginseng in Adults N/A
Completed NCT01678183 - Financial Incentives for Medication Adherence N/A
Completed NCT01694446 - Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose N/A
Completed NCT01426412 - A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol Phase 1
Completed NCT01131832 - Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols Phase 4
Completed NCT00758303 - A Study to Evaluate the Lipid Regulating Effects of TRIA-662 Phase 2/Phase 3
Completed NCT00534105 - Lipid Metabolism in Gestational Diabetes N/A
Recruiting NCT00408824 - Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study) N/A
Completed NCT00362206 - Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin Phase 3
Terminated NCT00299169 - Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes Phase 4
Completed NCT00381992 - Risk Assessment of Long-Haul Truck Drivers N/A
Completed NCT00414986 - Using Learning Teams for Reflective Adaptation for Diabetes and Depression N/A